Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

• Status: Completed
• Trial end date: 2017-01-03
• Target enrollment: 0
• Participant gender: Female

Summary

Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: David O'Malley
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Advanced Stage Endometrial Cancer (Stage 3 or 4)

• Any Histology including clear cell, and serous papillary carcinomas

• surgery must have had hysterectomy and bilateral salpingo-oophorectomy

• chemotherapy initiated 12 weeks after surgery

• sign informed consent

• Adequate End-organ function

• GOG (Gynecologic Oncology Group)Performance Status 0,1,2

• Patients must be 18 years or older

• Patients may have received radiation for the treatment of endometrial cancer.

• Patients may have measurable or non-measurable disease.

Exclusion Criteria:

• Patient with concomitant malignancy other than non-melanoma skin cancer

• Patients with prior malignancy who have been disease free for 5 years.

• Patients with serious uncontrolled infection, angina or serious peripheral neuropathy.

• Patients whose circumstances will not permit study completion or adequate follow up

• Patients who have received prior cytotoxic chemotherapy for treatment of endometrial cancer including chemotherapy used for radiation sensitization.